Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.

Blood Adv · 2023 · PMC10440472 · PMID 37285798

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

did not reach statistical significanceP = .064so close (0.05 < p ≤ 0.1)

In addition, we observed a trend toward delayed NK cell recovery at a high alemtuzumab exposure, but in this cohort the correlation did not reach statistical significance ( P = .064; electronic supplemental Material ; supplemental File 3; supplemental Figure 2 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.